Cefozopran hydrochloride

Research use only, not for human use.

Cefozopran hydrochloride is a fourth-generation cephalosporin. is a cell wall biosynthesis inhibitor with a broad spectrum of activity against Gram-positive and Gram-negative bacteria.

Cefozopran hydrochloride is a fourth-generation cephalosporin. is a cell wall biosynthesis inhibitor with a broad spectrum of activity against Gram-positive and Gram-negative bacteria.

Cefozopran (SCE-2787) is a fourth-generation cephalosporin that has good activity against gram-positive organisms including methicillin-susceptible staphylococci, enterococci, and viridans group streptococci; and against gram-negative organisms including hemophilus influenza. Moreover, cefozopran has comparatively good activity against enterococci and P. aeruginosa, which are refractory to other cephalosporins.

Cefozopran (SCE-2787) (5-80 mg/kg; s.c.; twice a day for 5 days; four-week-old ICR male mice) is effective against acute respiratory tract infections caused by Kiebsiella pneumonia DT-S. In the model of chronic respiratory tract infection caused by K. pneumoniae 27, Cefozopran (20-80 mg/kg; s.c.; twice a day for 7 days; five-week-old CBA/J female mice) is as effective as Ceftazidime.

SCE-2787 hydrochloride

GPCR/G Protein

Antibacterial

Bacterial

——

——

113981-44-5

551.99

C19H18ClN9O5S2

>98% (HPLC)

H2O:52 mg/mL (94.20 mM)

CO/N=C(\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-].Cl

——

(-20℃)

With Ice Pack

≥ 2 years